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Abstract
The rise of antibiotic resistances demands the acceleration of molecular diversification 
strategies to inspire new chemical entities for antibiotic medicines. We report here 
on the large-scale engineering of ribosomally synthesized and post-translationally 
modified antimicrobial peptides carrying the ring-forming amino acid lanthionine. 
New-to-nature variants featuring distinct properties were obtained by combinatorial 
shuffling of peptide modules derived from 12 natural antimicrobial lanthipeptides 
and processing by a promiscuous post-translational modification machinery. For 
experimental characterization, we developed the nanoFleming, a miniaturized and 
parallelized high-throughput inhibition assay. Based on a hit set of >100 molecules, 
we identified variants with improved activity against pathogenic bacteria and shifted 
activity profiles, and extrapolated design guidelines which will simplify the identifi-









Close to 75% of all approved antibiotics have their origin in nature, highlighting the 
importance of natural products for drug development1. However, identifying new 
lead molecules from this pool, preferably with novel modes of action, is becoming 
increasingly difficult2–5. The further development of existing molecules by chemical di-
versification, another well-established strategy6, delivers only limited structural novelty. 
More recently, biological diversification of enzymatically produced natural products 
(such as non-ribosomal peptides or polyketides) has been introduced. This strategy 
relies on the recombination of the involved enzyme clusters and delivered promising 
leads7,8. However, the lack of insight into how to generate sufficient modularity for 
efficient enzyme shuffling and the restricted experimental throughput to explore large 
combinatorial spaces limit the impact on drug development9,10.
In practical terms, molecule diversification in bioengineering approaches be-
comes much easier if the antimicrobial molecule is a gene product itself rather than 
the catalytic result of several gene products whose engineering has to be carefully 
coordinated. One such example of a gene-encoded natural product are ribosomally 
produced and post-translationally modified peptides (RiPPs)11. Here, application of the 
well- developed methods of DNA synthesis and modification allow direct synthesis of 
highly diverse peptides, which are then further modified with the functionally import-
ant post-translational modification machinery. Among RiPPs, the class of antimicrobial 
lanthipeptides (i.e. lantibiotics) represents a rich source for promising leads against 
Gram-positive bacteria. The best-known representative, nisin, already has as a long his-
tory as a food preservation agent and others entered recently into clinical development 
for infectious diseases12,13. Lantibiotics carry ring-forming amino acids (lanthionine 
and methyllanthionine) that result in small peptide stretches that are considerably 
restricted in their rotational degree of freedom (Figure 1a) and are introduced by an, 
often promiscuous, post-translational modification (PTM) machinery (Supplementary 
Figure 1), suggesting the possibility for diversifying the peptide backbone, while still 
enabling modifications14–19.
Lantibiotics commonly bind to the bacterial cell wall precursor lipid II, inhibiting 
cell wall formation and often also induce pore formation in the cytoplasmic membrane 
of their target cells20. They feature a similar blueprint encompassing the location of 
functional elements (lipid II binding and membrane piercing) as well as the organiza-
tion of the thioether rings within the peptide backbone (Figure 1a). However, the ring 
structures themselves vary considerably in size and primary structure over different 
peptides and the peptides display highly different degrees of activity towards target 
strains20. This diversity raises the intriguing opportunity of large-scale molecular 








ring structures and other functional segments (Figure 1b). In order to overcome the 
otherwise prohibitive issue of sorting through large numbers of peptide variants, we 
miniaturized Fleming’s inhibition zone assay21 by evaluating the result of coculturing 
RiPP producers and a sensor strain at nanoliter scale (“nanoFleming”) in nanoliter 
reactors (nLRs) and at high-throughput22–25. Here we present the results of shuffling 
33 lantibiotic peptide modules with natural or synthetic background yielding a library 
of 6,000 putatively active structures. Screening of the library with the nanoFleming 
platform followed by detailed characterization resulted in a set of 11 antimicrobial 
lanthipeptides that showed improved antimicrobial activity over wild-type peptides 
or were able to bypass resistance mechanisms.
Results
Design of a combinatorial lanthipeptide library
Peptide modules were recruited from twelve natural lantibiotics (Supplementary Ta-
ble 1) representing broadly linear peptides with lipid II binding and pore formation 
(type A lantibiotics, including nisin), globular peptides with large and intertwined rings 
with lipid II affinity, but without perforation capacity (type B lantibiotics, e.g. actagar-
dine), and peptides with a lipid II binding and a pore-forming subunit (two-component 
lantibiotics, e.g. haloduracin). The peptides were modularized according to rotationally 
restricted regions comprised of one single or two interwoven thioether rings and flex-
ible, interconnecting (“hinge”) regions. For nisin, we identified five modules (binding 
modules B1 and B2 involved in lipid II binding and pore modules P1 to P3 involved 
in pore formation, Figure 1a), extracted a further 23 modules from the remaining 11 
lantibiotics, and allocated those to positions B1 to P3 (Figure 1b). The set was completed 
with non-natural interconnecting hinge modules (P2) of different lengths and charges to 
increase the likelihood for activities against different target strains26 and a placeholder 
at P1 to represent natural lantibiotics missing this module (e.g. gallidermin). Finally, 
we limited B1 to modules from nisin and gallidermin as this module is critical for PTM 
by the nisin biosynthetic machinery (vide infra)17. Next, we generated new-to-nature 
peptides by randomly combining one module of each of the five groups, employing 
chemical synthesis of the peptide-encoding DNA and a split-and-mix approach to 
implement modular recombination (Supplementary Figure 2). PTM and export of 
lantibiotics are dependent on an N-terminal leader peptide; therefore the resulting 
DNA library of 6,000 combinatorial variants was fused to the leader peptide of nisin 
and overexpressed in a Lactococcus lactis also expressing the nisin PTM machinery 
NisBTC (i.e. including the nisin export function NisT but excluding the protease NisP 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Development of an inhibition assay at nanoliter scale
To enable rapid bioactivity assessment of the library peptides, we developed the nano-
Fleming high-throughput platform for antibiotic screening. We used small alginate 
hydrogel compartments (500 µm diameter, volume 65 nL, hence nLRs) for bacterial 
growth, peptide production and bioactivity testing. In a typical experiment, on aver-
age 0.3 library cells were encapsulated per nLR together with 150 cells of the sensor 
strain Micrococcus flavus. The nLRs were soaked in growth medium containing the 
soluble form of the protease NisP (NisPsol)27 required for the activation of secreted 
peptides (Supplementary Figure 3). Incubation, conducted in a hydrophobic phase to 
prevent cross-talk between nLRs, allowed for the growth of library and sensor cells and 
peptide production. After incubation and recovery from the hydrophobic phase, the 
nLR-embedded biomass was stained with the fluorescent dye SYTO 9 and nLRs with 
no or only very little biomass, indicating effective prevention of sensor strain growth, 
were isolated (Figure 2a and Supplementary Figure 4). To characterize the assay, we 
first compared the inhibition of nLR-embedded sensors in the presence and absence of 
colocalized prenisin-secreting cells and found that candidate strains secreting prenisin, 
but not a non-secreting control strain, efficiently inhibited the growth of the sensors 
(Figure 2b and Supplementary Figure 5). We also observed a higher sensitivity of the 
nanoFleming assay when compared to standard inhibition zone assays (Supplementary 
Figure 6). This corroborated the suitability of the miniaturized assay for the identifi-
cation of compounds in screening campaigns where production levels of the active 
substance might frequently be low.
Library screening and hit verification
Next, we screened the combinatorial peptide library using the nanoFleming platform 
(Figure 2c). Out of 3.2 × 105 nLRs, we isolated 839 nLRs (0.8%) containing very low 
levels of sensor biomass. The nLRs were spotted on agar plates and 617 of the embedded 
candidate strains (73.5%) could be regrown. We selected the 326 candidates that had 
shown the lowest green fluorescence in the screen for further processing. 
The peptide-encoding DNA sequences of all isolated clones were determined and 
205 unique peptide variants were characterized with respect to production level and 
antimicrobial activity. Each clone was grown in liquid culture, the secreted peptide 
was precipitated and the leader was fully cleaved with NisPsol. As only the sequence 
of the putatively antimicrobial core peptides but not the leader sequence varied, the 
production level and the fraction of correctly cleaved peptide could be estimated on the 
basis of the leader concentration by HPLCMSMS. Next, the activity of the mixture was 
analyzed with a conventional inhibition zone assay28 against M. flavus (Supplementary 
Figure 7) and a panel of model pathogens (Supplementary Figure 8). The activity data 








205 isolated clones, we identified 126 peptides that showed reproducible halo formation 
against M. flavus. Based on the DNA sequence data, heavily (modules from up to five 
different parents combined in a single peptide) as well as mildly shuffled antimicrobial 
peptides had been generated.
Design guidelines for bioactive lanthipeptides
We next set out to identify guidelines for the design of bioactive molecules based on 
the activity and secretion level of the 205 unique peptides obtained in the initial screen 
(126 positive, 79 negative). In order to ensure NisP cleavage, only two modules had 
been included for permutation at B1. Both were found in the screening hits and the 
corresponding peptides displayed considerable activity and production levels (Figure 3). 
At B2, the modules derived from gallidermin and nisin were clearly overrepresented 
in the fraction of the isolated peptides and seemed to facilitate processing and secre-
tion as compared to the remaining 4 options. Furthermore, all peptides bearing these 
two modules had a rather high activity, possibly indicating efficient processing of the 
peptide by the NisBTC PTM machinery17. At P1, the structural variety found within 
the subset of efficiently produced peptides was much larger than at B2 and modules 
derived from actagardine, nisin, paenibacillin, pep5 and subtilin were found. Similarly, 
modules from actagardine, nisin and paenibacillin were found in active bacterial vari-
ants. For P2 (hinge region), all modules showed production (at variable mean levels) 
and were represented among bioactive peptides. Similar results were observed for P3: 
All 5 possible modules were among the population of analyzed peptides, but we again 
observed a clear overrepresentation of the nisin-derived module. Still, all modules 
tested for P3 were included in bioactive peptides. Taken together, 22 of the 33 mod-
ules that had been shuffled were afterwards identified in newly generated bioactive 
peptides. These results indicate that antimicrobial lanthipeptides can be assembled 
by combinatorial recombination of peptide modules and that despite a considerable 
variation of the amino acid sequence, most of these modules can become part of novel 
and bioactive peptides.
Minimal inhibitory concentrations against pathogens
Based on their activity in the preliminary assays and their modular diversity, we selected 
61 peptides for further characterization. To facilitate the purification of the peptides 
in large quantities, we integrated a His6-tag into the leader peptide. Modified precur-
sor peptides were then purified via immobilized metal ion affinity chromatography 
(IMAC), the leader peptide was removed and the core peptides were further purified by 
RP-HPLC. For 31 peptides, this pipeline allowed purification of sufficient material to 
determine the minimal inhibitory concentration (MIC) against M. flavus and a panel 
























































































































































































































































































































































































































methicillin resistant Staphylococcus aureus, vancomycin resistant Enterococcus faecalis, 
vancomycin resistant E. faecium and Bacillus cereus.
We observed a large MIC-range of the purified peptides against the screening strain 
M. flavus, with many of the peptides exhibiting an MIC of <0.5 µg mL-1 (Supplemen-
tary Table 2 and Supplementary Figure 9). Furthermore, we identified peptides with 
improved activity against one or more of the pathogenic reference strains when com-
pared to nisin and gallidermin (Table 1). Nisin seems particularly active against both 
Enterococci and both Staphylococci strains and gallidermin against the two Streptococci 
strains. When combining the lipid II binding moiety B1 and B2 of gallidermin with the 
pore-forming modules P1-P3 of nisin, the combinatorial peptide 1 showed improved 
activities against Streptococci when compared to nisin and improved activities against 
one of the two Staphylococci and the two Enterococci when compared to gallidermin. 
The similar variant peptide 2 with an additional module exchange in P2 showed even 
better activity against the two Staphylococci and one Enterococci. Certain module 
combinations also led to peptides with strongly reduced activities against a specific 
strain, but retained a high specific activity against others, suggesting a possible increase 
in selectivity. For example, peptide 3 displayed good bioactivity against most strains of 
the test panel but activity against one of the Enterococci was strongly reduced when 
compared to nisin or gallidermin (Table 1).
Bypassing lantibiotic resistance mechanisms
Two specific microbial defense mechanisms against nisin are characterized29. One is 
constituted by the nisin immunity machinery, which is present in nisin-producing 




















































































B1 B2 P1 P2 P3
1 SC5.2712 Gallidermin Gallidermin Nisin Nisin Nisin 0.53 0.42 7.36 38.90 7.36 7.36 37.85
2 SC5.1421 Gallidermin Gallidermin Nisin Syn.1 Nisin 2.01 2.29 3.73 2.80 1.40 11.20 44.80
3 SC5.2930 Gallidermin Nisin Nisin Syn.3 Nisin 0.84 1.13 26.97 17.98 290.0 6.74 26.97
Gallidermin 0.90 1.81 11.30 13.56 27.12 54.25 37.29
Nisin 4.21 4.21 9.86 10.91 6.68 7.72 12.19
MICs of a selected set of combinatorial peptides against a panel of seven Gram-positive model pathogens. 
Values that are improved in comparison to one of the wild-type peptides nisin or gallidermin are highlighted 





strains. This is composed of the proteins NisI and NisFEG, which prevent nisin bind-
ing to lipid II. The second mechanism is the nisin resistance protein (NSR) present in 
non-producing (pathogenic) strains. NSR works as a peptidase that cleaves the linear 
C-terminus of nisin (last 6 amino acids) after the interwoven rings DE and increases 
the MIC 20-fold. In the latter case, ring E is crucial for recognition29,30. We have iden-
tified both, peptides for which the natural nisin immunity system showed only reduced 
effectiveness by testing L. lactis NZ9803 expressing NisI and NisFEG (Table 2a) and 
for which a natural resistance determinant, the NSR from S. agalactiae, heterologously 
expressed by L. lactis NZ9000 [pNSR], no longer showed any activity (Table 2b).
Inference of structural features
Next to the bioactivity of those combinatorial peptides we were interested in the degree 
of post-translational modification introduced by NisB and NisC. We therefore analyzed 
Table 2. MICs (µg mL1) of combinatorial peptides against nisin resistant strains.
a
MIC [µg mL1] Module combination L. lactis
NZ9000
L. lactis
NZ9803 ImmunityPeptide B1 B2 P1 P2 P3
1 SC5.2712 Gallidermin Gallidermin Nisin Nisin Nisin 0.05 1.30 25
3 SC5.2930 Gallidermin Nisin Nisin Syn.3 Nisin 0.12 1.90 15
4 SC5.1659 Nisin Nisin Nisin Syn.2 Nisin 0.80 12.00 14
5 SC5.1536 Nisin Nisin Nisin Syn.4 Nisin 0.13 3.60 27
6 SC5.0925 Nisin Gallidermin Nisin Syn.3 Nisin 0.03 4.00 132
Nisin 0.03 30.90 1029
b






[pNSR] ResistancePeptide B1 B2 P1 P2 P3
7 SC5.0718 Nisin Nisin Nisin Pep 5 Lactocin S 0.65 0.65 0
8 SC5.2096 Nisin Nisin Nisin Nisin Pep 5 0.73 0.73 0
9 SC5.0364 Nisin Nisin Nisin Syn.3 Pep 5 2.15 2.15 0
10 SC5.2354 Nisin Nisin Nisin Syn.4 Paenibacillin 6.90 6.90 0
11 SC5.0479 Nisin Nisin Nisin Syn.2 Epilancin K7 0.86 1.73 1
Nisin 0.08 1.63 19
(a) MICs of a selected set of nisin-alike combinatorial peptides against a strain carrying the nisin immunity 
cluster on the genome (L. lactis NZ9803) and comparison to a strain that does not carry the cluster (L. lactis 
NZ9000). (b) MICs of a selected set of combinatorial peptides with various C-termini against a strain over-
expressing the nisin resistance protein from a plasmid (NZ9000 [pNSR]) and comparison to a strain that 
carries an empty plasmid (NZ9000 [pEmpty]). Immunity and resistance are given as relative change (x/y-1). 








the final set of 11 peptides with improved activity against the pathogenic reference 
strains (Table 1) and the ability to bypass defense mechanisms (Table 2) by mass spec-
trometry. As the major modification pattern for all peptides analyzed we could identify 
a degree of dehydration of serine and threonine residues that is in the range of nisin 
(70 to 100%, nisin: 89%) and observed that except for peptide 7 (3 of 4) and peptide 10 
(4 of 7) all cysteines were involved in thioether ring formation (Supplementary Figs. 10 
and 11) and confirmed the success of the combinatorial design of novel lanthipeptides.
Discussion
Large-scale engineering of natural products is a promising strategy to obtain improved 
bioactive molecules but is suffering from two bottlenecks: a lack of insight into the 
determinants of functional modularity in large enzyme clusters and a lack of efficient 
methods to explore the antimicrobial activity of large sets of variants at high speed. 
Here, we show that assays for antimicrobial activity can be efficiently downscaled 
and parallelized, making the latter bottleneck obsolete. By switching from natural 
products whose structure is encoded in the reaction specificity of enzymes to those 
that are gene-encoded, such as lantibiotics, we drastically facilitate the production 
of potentially active molecule variants. We do not entirely escape the boundaries of 
enzyme specificity with this approach, as enzyme-based PTMs remain important, but 
the availability of promiscuous PTM systems as well as the sheer number of variants 
that DNA-manipulation can deliver in screens of the type demonstrated here, make the 
successful isolation of novel active, peptide-based natural products much more likely. 
We illustrate this by modular shuffling of lantibiotics, for which we could easily isolate 
126 novel active antimicrobial peptides combining modules from other lantibiotics or 
of synthetic nature and some of them displaying improved or shifted activity profiles.
The presented strategy is scalable without adaptation of the protocol by increasing 
the number of modules, and it can readily be adapted to other pathogenic hosts31 as 
well as to other library generation methods. In this study we focused on lipid II binding 
peptides and the nisin modification machinery. However, the strategy is applicable 
to all antimicrobial peptides as long as they are secreted by the producing host. We 
envision that the use of more diverse peptide modules, including those exhibiting a 
different mode-of-action, will enhance the diversity of the isolated bioactive peptides.
A bottleneck that cannot be entirely excluded is the substrate specificity of the PTM 
enzymes that limit the diversity of peptides that can be produced. However, given the 
capacity of the nanoFleming assay, future approaches might include various different 
PTM enzymes co-expressed in the production host or even include direct evolution 
on such enzyme to broaden their substrate specificity and therefore widen the diversity 











the length of the antimicrobial peptides in the library is currently restricted by the 
capabilities of chemical DNA synthesis (approx. 150 bases), which is sufficient for 
many RiPP genes, but can be extended using oligo-synthesis together with established 
assembly-strategies32. Also, the nanoFleming assay can be easily scaled to up to 106 
clones per day, which is the current limit for large particle flow cytometry. In sum-
mary, the presented platform represents a powerful novel approach to the generation 
of topologically novel antimicrobial peptides.
In the future, this platform might not only be useful for the discovery of molecules 
with improved or altered bioactivity profiles but also for the generation of sufficient 
diversity required at other steps in drug development of peptides (e.g. to test candidate 
peptides for plasma stability or activity in vivo). Last, we envision the nanoFleming 
platform of help also for addressing other questions in peptide development, such as 
for the improvement of peptide secretion from host strains by genetic engineering.
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SI Methods
Chemicals and molecular biology
Unless otherwise noted, chemicals were obtained from Sigma-Aldrich (St. Louis, MO, 
USA), DNA purification kits from Zymo Research (Irvine, CA, USA) and enzymes 
from NEB (Ipswich, MA, USA). Sanger-sequencing was done externally (Microsynth, 
Balgach, Switzerland, and GATC Biotech, Konstanz, Germany) using an appropriate 
primer (see Supplementary Table 3 for a list of DNA oligonucleotides). For peptide and 
protein purifications, IMAC equilibration buffer consisted of 500 mM sodium chloride 
and 20 mM sodium phosphate buffer, pH 7.4; IMAC wash buffer of 20 mM imidazole, 
500 mM sodium chloride and 20 mM sodium phosphate buffer, pH 7.4; IMAC elution 
buffer I of 500 mM sodium chloride and 475 mM sodium acetate/acetic acid buffer, 
pH 3.5 and IMAC elution buffer II of 500 mM imidazole, 500 mM sodium chloride and 
20 mM sodium phosphate buffer, pH 7.4. Cleavage of leader peptides with NisPsol was 
done in NisP cleavage buffer containing 100 mM ammonium acetate/acetic acid, pH 6.0.
Bacterial strains and cultivations
Cloning was done using either Escherichia coli DH5α or E. coli DB3.1 (Thermo Fisher 
Scientific, Waltham, MA, USA, see Supplementary Table 4 for a list of strains) cul-
tivated in 14 mL polypropylene tubes (Greiner, Kremsmünster, Austria), filled with 
5 mL LBMiller broth (Difco, Becton Dickinson, Franklin Lakes, NJ, USA) and incu-
bated at 37 °C with aeration on a shaker (Kuhner, Birsfelden, Switzerland) operated at 
200 rpm and 25 mm amplitude. Strain Lactococcus lactis NZ9000, harboring the genes 
for NisB, NisT and NisC on plasmid pIL3BTC (see Supplementary Table 5 for a list of 
plasmids) was cultivated in 14 mL polypropylene tubes filled with M17 broth (Difco) 
supplemented with 5 g L−1 glucose (GM17 broth) and incubated at 30 °C without aera-
tion. For screening and peptide production a chemically defined medium (CDM) was 
used. CDM contained 83.26 mM glucose, 150.00 mM 2(Nmorpholino)ethanesulfonic 








manganese(II) chloride, 0.24 µM ammonium molybdate, 1.07 µM cobalt(II) sulfate, 
1.20 µM copper(II) sulfate, 1.04 µM zinc sulfate, 20.12 µM iron(III) chloride, 9.69 µM 
(±)αlipoic acid, 2.10 µM Dpantothenic acid, 8.12 µM nicotinic acid, 4.91 µM pyridoxal 
hydrochloride, 4.86 µM pyridoxine hydrochloride, 2.96 µM thiamine hydrochloride, 
0.41 µM biotin, 1.46 mM Lalanine, 1.40 mM Larginine, 0.61 mM Lasparagine, 1.03 mM 
Laspartic acid, 0.35 mM Lcysteine, 0.66 mM Lglutamic acid, 0.66 mM Lglutamine, 
0.39 mM glycine, 0.16 mM Lhistidine, 0.63 mM Lisoleucine, 0.89 mM Lleucine, 1.02 mM 
Llysine, 0.26 mM Lmethionine, 0.39 mM Lphenylalanine, 3.58 mM Lproline, 1.64 mM 
Lserine, 0.57 mM Lthreonine, 0.18 mM Ltryptophan, 2.76 mM Ltyrosine, 0.73 mM 
Lvaline. Depending on the application, CDM medium was further supplemented: 
CDMS (for nanoFleming screening) contained in addition 9.00 mM potassium phos-
phate and 7.04 mM calcium chloride and was adjusted to pH 6.5 with sodium hydrox-
ide. CDMV (for peptide precipitation) contained in addition 20.00 mM potassium 
phosphate, 20.00 µM calcium chloride, and 10.00 g L−1 tryptone and was adjusted to 
pH 7.0. CDMP (for peptide purification) contained in addition 20.00 mM potassium 
phosphate, 20.00 µM calcium chloride, 5.00 g L−1 tryptone and was adjusted to pH 7.0. 
All media were supplemented with the appropriate antibiotics for plasmid maintenance: 
for E. coli, 20 µg mL−1 chloramphenicol, 250 µg mL−1 erythromycin, and/or 50 µg mL−1 
kanamycin; for L. lactis, 10 µg mL−1 chloramphenicol and/or 10 µg mL−1 erythromycin. 
Micrococcus flavus NIZO B423 was cultivated in LBMiller broth and incubated at 30 °C 
with aeration. The indicator strains used in inhibition zone assays, Staphylococcus aureus 
ATCC 29213 and ATCC 33591 were cultivated in cation adjusted MuellerHinton broth 
(MHB 2, Difco) and incubated at 37 °C with aeration. Enterococcus faecalis ATCC 29212 
and ATCC 51575 were incubated in ToddHewitt broth (Difco) and incubated at 37 °C 
with aeration. Streptococcus pneumoniae ATCC 49619 was cultivated in ToddHewitt 
broth supplemented with 10% fetal bovine serum (FBS, P303302, Milian Analytica, 
Rheinfelden, Switzerland) and incubated at 37 °C without aeration. The strains used for 
MIC testing, S. aureus CAL and MW2, E. faecalis LMG 16216, E. faecium LMG 16003 
and Bacillus cereus ATCC 14579 were cultivated in MuellerHinton broth (MHB, Difco). 
S. pneumoniae TIGR4 and D39 were cultivated in MHB supplemented with 5% defi-
brinated sheep blood (Oxoid, Thermo Fisher Scientific). The strain L. lactis NZ9803 
displaying nisin immunity was based on L. lactis NZ9800 that was genome engineered 
to carry a deletion of the nisP gene using a method described previously33. Expression 
of the immunity cluster was induced by adding 5 ng mL−1 nisin (from a 1 mg mL−1 stock 
in 0.05% aqueous acetic acid) to the medium. Strain L. lactis NZ9000 [pNSR], overex-
pressing the nisin resistance protein from a plasmid30 was cultivated as described for 
NZ9000 but adding 5 ng mL−1 nisin and 10 µg mL−1 chloramphenicol to the medium 
to induce the expression of the nsr gene and maintain the plasmid, respectively. In case 







Synthesis and cloning of the DNA library
The combinatorial peptide library was synthesized without the leader peptide sequence 
as DNA oligonucleotide representing the antisense strand and using solid phase synthe-
sis (see Supplementary Figure 2) by Ella Biotech GmbH (Martinsried, Germany). It was 
flanked by 5’ and 3’ primer binding site for second strand synthesis (see Supplementary 
Table 6 for the DNA oligonucleotide sequences of the modules). The second strand 
was synthesized in a primer extension reaction using the oligonucleotide mixture and 
the primer lib2ndfw in a 1:1 stoichiometric ratio (approx. 20 pmol each in 50 µl) to-
gether with 3 units of Phusion High-Fidelity DNA Polymerase (New England Biolabs, 
Ipswich, MA) using standard PCR reaction conditions. The double stranded product 
was purified using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA) 
and cloned into plasmid pSEVA241silent. The plasmid features transcriptional termi-
nators 5’ and 3’ to the cloning site and it contains a ccdB expression cassette between 
NheI and HindIII cloning sites for efficient elimination of religands34. The plasmid 
was generated by amplifying the ccdB cassette using primers ccdBBamHINheIfw and 
ccdBHindIIIrv from plasmid pQL11 and then inserted into the multiple cloning site 
of pSEVA241. After plasmid proliferation in the CcdB resistant E. coli DB3.1 and 
Sanger-sequencing using primer pSEVAt1fw and pSEVAt0rv, the library DNA was 
cloned into pSEVA241silent using E. coli DH5α. Growth of the transformants was 
done on large Petri dishes (145 mm diameter, Greiner) filled with 50 mL of LB-Miller 
agar and by plating approx. 1 × 104 colony forming units (CFUs) per plate (10 plates 
in total = approx. 15fold oversampling of the library). After incubation, the biomass 
was scraped off the plates and plasmid library pSEVA241library was isolated.
Next, the library was cloned into the screening plasmid pNZE3rdmmcherry. This 
plasmid was derived from plasmid pNZE3nisA and served as shuttle for transfer of 
the library from E. coli to L. lactis. The plasmid was first modified to add the gene for 
the red fluorescent protein mCherry. The gene was PCR-amplified from the BioBrick 
part BBa_J06504 in plasmid pSB1C3 using primers mcherryNdeIfw and mcherry-
HindIIIBamHIrv. Next, the constitutive promoter P2335 was PCR-amplified together 
with the RBS and the first 21 bases of the P23 regulated gene from the chromosome of 
L. lactis NZ9000 using primers P23HindIII-NheIfw and P23NdeIrv. Both PCR-products 
were digested with NdeI, ligated and the ligation-product was amplified using primers 
P23HindIII-NheIfw and mcherryBamHIrv, followed by a digest with NheI and BamHI. 
The same restriction sites were integrated into the plasmid pNZE3nisA using enzy-
matic inverse PCR36 and the primers pNZE3pNGNheIfw and pNZE3pNGBamHIrv, 
which also contained a BsaI restriction site on both ends to circularize the plasmid. 
Next, the promoter::mcherry fusion was cloned into that plasmid and NheI site was 
removed using a modified QuickChange protocol37 and primers mcherry-NheIrmfw 








nisA expression cassette was replaced by the cassette nis-fragment-BglII-HindIII con-
taining the nisin-inducible promoter Pnis, the gene for the nisin leader peptide and 
the nisin structural gene (both genes were codon optimized for L. lactis MG1363) 
where a NheI restriction site was added between structural gene and the gene en-
coding for the leader peptide to facilitate the cloning of the leader-less library genes. 
The cassette was custom-synthesized (Geneart, Regensburg, Germany) and isolated 
from plasmid pMATnisAopt by digesting with enzymes BglII and HindIII cloned 
into pNZE3nisAmcherry to result in plasmid pNZE3nisAoptmcherry. As a last step, 
the nisA structural gene was removed from that plasmid by digestion with NheI and 
HindIII and ligation of a random DNA-fragment, assembled by the annealing of the 
oligonucleotides rdmNheIHindIIIfw and rdmNheIHindIIIrv and resulted in plasmid 
pNZE3rdmmcherry. All pNZ-based plasmids were Sanger-sequenced using primers 
pNZE3-seq-fw or pNZE3-seq-rv.
The library was then transferred from the pSEVA241library to pNZE3rdmmcherry 
via NheI and HindIII to obtain the plasmid library pNZE3librarymcherry which was 
then used to transform strain E. coli DH5α. The transformants were grown on large 
Petri dishes filled with 50 mL LB-Miller agar supplemented with the appropriate anti-
biotics and by plating approx. 5 × 106 CFUs per plate (10 plates in total). The biomass 
was scraped off the plate and the plasmid was isolated. In the final step, the screening 
strain L. lactis NZ9000 [pIL3BTC] was transformed with the plasmid library to yield 
the candidate cells. The transformation mixture was again plated on large Petri dishes, 
this time filled with 50 mL GM17 agar, supplemented with the appropriate antibiotics 
and the cells were scraped off after growth for 48 h. The strain was diluted in liquid 
culture (GM17 broth, supplemented with appropriate antibiotics) to an OD600 of 0.5 
and incubated at 30 °C for 3 h. The culture was then supplemented with glycerol to a 
volume fraction of 20%, 1 mL aliquots were frozen at 80 °C and the colony forming 
units (CFUs) of the stock were determined by plating.
Library quality control
The modular composition of the library was analyzed by next generation sequencing 
(Illumina MiSeq platform) at the following stages: (I) directly after second strand syn-
thesis; (II) in plasmid pSEVA241library after library cloning in E. coli; (III) in plasmid 
pNZE3librarymcherry after library cloning in E. coli, and (IV) after transfer to L. lactis. 
The double-strand DNA fragment from stage I was directly used for sequencing. For 
stage II, III and IV, the library fragment was isolated from the plasmids by NheI and 
HindIII digestion followed by purification with an agarose gel. The linear DNA frag-
ments were processed as recommended by the MiSeq Reagent Kit and sequenced in 
a paired-end run with 251 cycles on a MiSeq device (Illumina, San Diego, CA, USA) 







processed using the software bcl2fastq, version 2.18.0.12 (provided by the device man-
ufacturer) and the resulting FASTQ files from each sequencing run were processed 
using an in house written software to identify module counts, sequence mismatches 
and indels. The resulting datasets were used to judge bias and error rate of each of the 
synthesis and cloning steps (see Supplementary Figure 2).
nanoFleming screening
Depending on the experiment, the candidate strain either carried a plasmid for secretion 
of prenisin (pNZE3nisAmcherry = positive control), an empty plasmid (pNZE3rdmm-
cherry = negative control) or the plasmid library (pNZE3librarymcherry). As sensor 
strain, M. flavus (NIZO B423) or L. lactis NZ9000 [pNGnisTPtdgfp] was used. En-
capsulation of cells into nLRs was done as previously described24 using laminar-jet 
breakup (VAR D encapsulator from Nisco Engineering, Zürich, Switzerland) of a 
sodium alginate solution (20 g L−1 alginate in water, sterile-filtered) and using bac-
terial glycerol stocks. CFUs were adjusted such that on average each nLR contained 
0.3 candidate cells and 150 sensor cells. The encapsulator was operated at 0.7 kHz with 
a flow rate of 3.3 mL min−1 and a nozzle diameter of 150 µm. Reactors were solidified 
in nLR hardening buffer (1 mM tris(hydroxymethyl)aminomethane hydrochloride 
(TrisHCl) pH 7.0, 100 mM CaCl2) for 20 min, and briefly rinsed with nLR wash buffer 
(1 mM TrisHCl pH 7.0, 10 mM CaCl2). The average nLR diameter after hardening 
was 460 µm (approx. 50 nL, CV: 4 to 7%). The nLRs where then transferred to CDMS 
medium (100 g nLR L−1 and incubated for 6 h at 30 °C on a shaker (200 rpm, 25 mm 
amplitude, Kuhner, Birsfelden, Switzerland). The nutrients provided in this medium are 
not sufficient for growth of the sensor but allow for growth of the candidate (candidate 
head start). After 6 h, the medium was supplemented with 5 ng mL−1 nisin to induce 
peptide production. After an additional hour of incubation, 10 g L−1 tryptone was added 
(from a 100 g L−1 stock in water) to allow for the growth of the sensor. Furthermore, 
the protease NisPsol was added (only if not already expressed by the sensor strain) at 
a final concentration of 0.2 µg mL−1 (from a 20 µg mL−1 enzyme stock in 100 mM MES 
buffer, pH 6.0). The nLRs were incubated for another hour and then removed from the 
medium using a cell strainer (100 µm mesh size, Falcon, Becton Dickinson, Franklin 
Lakes, NJ, USA) and an aliquot of approx. 1 g (wet weight, approx. 2 × 104 nLRs) was 
added to a 50 mL centrifugation tube pre-filled with 45 mL of a hydrophobic phase 
(mineral oil heavy, Carl Roth, Karlsruhe, Germany), supplemented with surfactants 
(40 g L−1 Span80 and 10 g L−1 Tween85). Emulsification was achieved by vigorous 
shaking, the whole content of the tube was poured into a large Petri dish (145 mm 
diameter) and incubated at 30 °C for 18 h.
After incubation, the emulsion was transferred into a sterile glass beaker and the oil 








10 mL of wet nLRs per tube) and washed several times with nLR wash buffer supple-
mented with 0.1 g L−1 Tween20, followed by centrifugation (1,000x g, 1 min) until all 
remaining oil was removed. The nLRs were then transferred to 50 mL of fresh nLR wash 
buffer and the biomass was stained (if not labeled by tdGFP) by the addition of 1 µM of 
SYTO 9 (from a 5 mM stock in DMSO, Thermo Fisher Scientific) followed by incubation 
in the dark for 1 h at room temperature at approx. 20 rpm on a benchtop roller incubator.
The nLRs were then analyzed using a large-particle flow-cytometer (BioSorter, 
Union Biometrica, Holliston, MA)23. The device was operated with water as sheath fluid 
and analysis was done with extinction at 488 nm as a trigger signal and recording data 
for time-of-flight (TOF, as a relative estimate of the particle size), extinction at 488 nm, 
green fluorescence (sensor, excitation laser 488 nm, beam splitter DM 562, emission 
filter BP 510/23 nm) and red fluorescence (candidate, excitation laser 561 nm, TR mirror, 
emission filter BP 615/24 nm). Signal analysis and selection of subpopulations was done 
using the Flow Pilot software, version 1.3.08 (provided by the device manufacturer). 
Data analysis was done using the FlowJo software, version 10.1 (FlowJo LLC, Ashland, 
OR, USA). Prior analysis of the library, samples containing nLR with embedded colo-
nies of the positive control and negative control were analyzed. For library screening, 
nLRs displaying low green fluorescence intensity levels (lower than the mean green 
intensity of the negative control by at least 3 σ) were sorted into a 50 mL centrifugation 
tube prefilled with 10 mL nLR wash-buffer (device specific ‘enrichment mode’, max. 
150 Hz sorting rate). Then, isolated nLRs were subjected to another sorting (‘pure mode’, 
max. 1 Hz sorting rate), this time spotted into Nunc MicroWell 96well plates (167008, 
Thermo Fisher Scientific) filled with 100 µL of GM17 broth which was supplemented 
with 10 µg mL−1 chloramphenicol and 10 µg mL−1 erythromycin to allow for selective 
recovery of the candidate strain while killing the sensor strain. The plates were sealed 
(airtight aluminum foil) and incubated at 30 °C for 72 h without shaking to expand 
the candidate strain from the nLR. Cultures in the wells were then supplemented with 
glycerol to a final volume fraction of 20%, the plates were sealed and frozen at 80 °C.
Fluorescence microscopy
Microscopic analysis of nLRs was carried out with the inverted fluorescence micro-
scope Axio Observer II equipped with an AxioCam MR3 camera (Carl Zeiss Micros-
copy, Jena, Germany) either using bright-field or epifluorescence with filter cubes 
(for GFP, SYTO 9: excitation BP 470/40 nm, beam splitter DM 495 nm, emission 
BP 525/50 nm; for mCherry: excitation BP 565/30 nm, beam splitter DM 585 nm, 
emission BP 620/60 nm). Images were taken using the AxioVision software, version 
4.8.2 SP3 (provided by the device manufacturer). If bright-field and epifluorescence 
were recorded from the same object, images were stored as overlays of both channels. 







Peptide identification and precipitation
For each peptide, a culture in 10 mL GM17 broth inoculated from a single colony 
of the peptide producing strain was prepared. After growth, 6 mL of the culture was 
used to isolate the plasmid and the peptide gene was Sanger-sequenced using primer 
pNZE3seqfw. Next, the peptide was precipitated by trichloroacetic acid (TCA)40. For 
this, 90 mL of CDM-V medium supplemented with the appropriate antibiotics and 
5 ng mL−1 nisin was inoculated with 900 µL from the GM17 culture. After 24 h of in-
cubation, the cells were pelleted by centrifugation (3,200× g, 30 min). The peptide was 
precipitated by adding 10 mL of an ice-cold, saturated trichloroacetic acid solution (in 
water) to the supernatant and freezing (−20 °C) the mixture for >2 h. After thawing, 
the precipitated peptide was pelleted by centrifugation (48,000× g, 30 min 4 °C) and 
washed once with ice-cold acetone followed by a second centrifugation. The pellet was 
dried at room temperature and resuspended in 1 mL of an 0.05% aqueous acetic acid 
solution. Next, the leader peptide was cleaved off using 750 µL of the peptide solution, 
250 µL of 4× NisP cleavage buffer and NisPsol at a final concentration of 0.2 µg mL−1 
(from a 20 µg mL−1 enzyme stock). The mixture was incubated at 37 °C until complete 
cleavage was achieved (approx. 36 h, monitored by HPLCMSMS, see below). Each 
peptide was precipitated in duplicate.
Leader peptide quantification
The amount of leader peptide in the NisPsol treated peptide samples was quantified by 
HPLCMSMS using an Agilent 1200 series HPLC system coupled to an Ab Sciex 4000 
QTRAP triple quadrupole mass spectrometer (operated with Analyst software, version 
1.6.3, Ab Sciex, Framingham, MA) and using electrospray ionization (ESI). An aliquot of 
3 µL of the peptide sample was injected onto a RPC18 column (ReproSil-Pur Basic C18 
3 µm, 50 × 3 mm, Dr. Maisch, Ammerbuch, Germany), heated to 30 °C and operated 
with water supplemented with 0.1% formic acid as solvent A and acetonitrile supple-
mented with 0.1% formic acid as solvent B (all solvents MSgrade). The column was 
equilibrated at 10% solvent B prior injection. After injection, a gradient was imposed 
from 10% solvent B to 35% solvent B in 180 s at a flow rate of 800 µL min-1. The column 
was washed with 95% solvent B for 45 s at 1,500 µL min-1 and equilibrated with 10% 
solvent B for 60 s at 1,500 µL min-1. Usually three leader peptide peaks were observed: 
peptide 1, without methionine, resulting from cleavage by endogenous methionine 
aminopeptidases; peptide 2, with a non-formylated methionine at the N-terminus; pep-
tide 3, with a formylated methionine at the N-terminus. For quantification of the leader 
peptides, the mass spectrometer was operated in multiple reaction monitoring (MRM) 
mode. The parameters for the TurboIonSpray probe: ion spray voltage (IS): 5,000 V, 
positive polarity, temperature (TEM): 700 °C, curtain gas (CUR): 20 psig, ion source 








the settings for the MS: declustering potential (DP): 80 V, entrance potential (EP): 10 V, 
collision energy (CE): 45 V, collision cell exit potential (CXP): 15 V and collision gas 
(CAD): 4 psig. Quantification was done for the fragment ion (Q3) at 574.4 m/z orig-
inating from the mother ions (Q1) from leader peptide 1 at 589.4, 784.9, 1,176.6 m/z, 
from leader peptide 2 at 622.0, 829.0, 1,242.5 m/z and from leader peptide 3 at 629.0, 
838.0, 1,256.5 m/z with 50 ms dwell time. Signal peaks were integrated using Analyst 
software, version 1.6.3 (provided by the device manufacturer) and the sum of the peaks 
was normalized to the leader amount that resulted from a precipitated prenisin control 
(relative quantification). Measurements were performed in triplicate.
Inhibition zone assay
The antimicrobial activities of the precipitated peptides were confirmed using an 
inhibition zone assay28. The strains M. flavus (NIZO B423), S. aureus MSSA (ATCC 
29213) and MRSA (ATCC 33591), E. faecalis VSE (ATCC 29212) and VRE (ATCC 
51575) and S. pneumoniae (ATCC 49619) were used as sensor strains. Plates were as-
sembled using 50 mL of the strain-specific agar, cooled to 40 °C and mixed with 2 mL 
of a culture at an OD600 of approx. 1. The mixture was poured into large Petri dishes 
(145 mm diameter) and cooled to room temperature. Using a stamp, 19 holes (3 mm 
diameter) were inserted into the agar and 50 µL of the samples were pipetted into each 
hole. Plates were incubated for 24 h and imaged using a flatbed scanner. Zone areas were 
measured using the Fiji software38,39. Inhibition zone areas were normalized to areas 
that resulted from a precipitated nisin control (relative quantification). Measurements 
were performed in triplicate.
Peptide production and purification
The leader peptide of each variant was equipped with a His6tag followed by an addi-
tional tryptophan (HWtag, see Supplementary Table 7 for DNA and peptide sequences). 
The tag was integrated by enzymatic inverse PCR using primers tagHisWBsaIfw and 
tagHisWBsaIrv, the product was cleaved with BsaI and re-circularized by ligation. The 
mix was used to transform L. lactis NZ9000 [pIL3BTC]. The integration of the tag was 
confirmed by Sanger-sequencing using primer pNZE3seqfw.
For peptide purification, a 25 mL CDMP preculture, supplemented with the ap-
propriate antibiotics, of the peptide producing strain was incubated overnight. Then, 
20 mL of the culture was used to inoculate 2 L of CDMP medium supplemented with 
the same antibiotics and 10 ng mL−1 nisin. The culture was incubated without shaking 
until it reached stationary phase (after 24 to 36 h). After incubation, the cells were 
pelleted by centrifugation (6,000× g, 30 min). The pH of the supernatant was adjusted 
to 7.0, filtered through a bottle-top filter (0.22 µm pore size, PES membrane, Stericup, 







50 mL of 70% isopropanol, 0.4% TFA and stirred at room temperature for 2 h to separate 
cell-bound peptides from pellet components. After centrifugation (3,200× g, 10 min), 
the cell pellet was discarded and the isopropanol in the supernatant was removed with 
a rotary evaporator at 40 °C and 40 mbar for 10 min. The pH of the remaining solution 
was adjusted to 7.0 with NaOH and added to the previously retained supernatant for 
further treatment on an ÄKTAexplorer chromatography system (operated with Uni-
corn software version 5.31, GE Healthcare, Chicago, IL). The system was connected 
to a NiSepharose EXCEL column (XK 16/20, 10 mL bed volume, GE Healthcare) 
equilibrated with 5 column volumes (CV) of IMAC equilibration buffer. The culture 
supernatant was loaded onto the column at a flow rate of 10 mL min1. The column was 
washed with 10 CV of IMAC equilibration buffer. The peptides were eluted with 3 CV 
of IMAC elution buffer I followed by 3 CV of IMAC elution buffer II. The whole elu-
tion fraction (60 mL) was collected and then loaded onto a Sephadex G15 column (XK 
50/30, 300 mL bed volume) for desalting that was equilibrated with 5 CV of desalting 
buffer pH 4.0 (100 mM ammonium acetate/acetic acid buffer, pH 4). The same buffer 
was used for elution. The elution fraction corresponding to the peptide (monitored at 
280 nm absorbance) was collected (approximately 100 mL), frozen at −80 °C for >2 h 
and lyophilized (approx. 60 h) using a freeze-dryer (Alpha 12 LDplus, Christ, Osterode, 
Germany), connected to a vacuum pump (RC6, Vacuubrand, Wertheim, Germany).
To remove the leader peptide, the freeze-dried peptides were dissolved in 40 mL of 
NisP cleavage buffer containing NisPsol at a concentration of 0.2 µg mL−1 and incubated 
at 37 °C for 16 h. Cleavage of the leader peptide was monitored by HPLC (see below). 
When incomplete, more NisPsol was added. For HPLC analysis an aliquot of 3 µL of 
the peptide was injected onto an RPC18 column (ReproSil-Pur 120 C18-AQ 3 µm, 
150 × 2 mm, 5 × 2 mm precolumn, Dr. Maisch) heated to 30 °C and operated at a flow 
rate of 300 µL min-1 with water supplemented with 0.1% TFA as solvent A and acetoni-
trile supplemented with 0.1% TFA as solvent B (all solvents MSgrade). The column was 
equilibrated with 20% solvent B prior injection. After injection and an initial wash step 
of 2.8 min a gradient was imposed from 20% solvent B to 50% solvent B in 16 min. The 
column was washed with 95% solvent B for 5 min and equilibrated with 20% solvent B 
for 9.2 min. Peptide elution was monitored at an absorbance of 205, 254 and 280 nm.
HPLC-purification of the cleaved peptides was performed on an ÄKTAexplorer 
chromatography system. The complete peptide sample was injected onto a RPC18 
column (PRONTOSIL 120 C18 10 µm, 250 × 20 mm, 50 × 20 mm precolumn, Bischoff, 
Leonberg, Germany), heated to 30 °C and operated at a flow rate of 10 mL min-1 and 
with water supplemented with 0.1% TFA as solvent A and acetonitrile supplemented 
with 0.1% TFA as solvent B. The column was equilibrated with 20% solvent B prior 
injection. After injection and an initial wash step of 6 min a gradient was imposed 








solvent B for 8 min and equilibrated with 20% solvent B for 13 min. Peptide elution 
was monitored at an absorbance of 205 nm and peptide peaks were collected. The 
fractions were frozen at −80 °C for >2 h and lyophilized (approx. 18 h) using a freeze-
dryer (Alpha 2-4 LDplus, Christ), connected to a vacuum pump (RC6, Vacuubrand). 
In case where a peptide resulted in several peaks (e.g. due to different PTM patterns 
of the same translation product), all peaks were MIC-tested (see below) but only the 
peak with the highest activity was processed further.
NisP production
The protease was secreted as soluble form (NisPsol) where the membrane anchor of 
the enzyme was replaced by a His8-tag and expressed from plasmid pNZnisPsol-8H. 
For production, a 10 mL GM17 preculture, supplemented with the appropriate anti-
biotics, of the strain was used to inoculate a 1 L production culture in GM17 broth, 
supplemented with the same antibiotic. At an OD600 of 0.7, 5 ng mL−1 nisin was added 
and incubation was continued for 18 h and the culture was processed as described for 
the peptide purification. Purification was done on an ÄKTAexplorer chromatography 
system and using a Sepharose 6 Fast Flow column (GE Healthcare), loaded with Co2+ 
ions (XK 16/20, 10 mL bed volume) equilibrated with 5 CV of IMAC equilibration 
buffer. The supernatant was loaded onto the column at a flow rate of 5 mL min−1. The 
column was washed with 10 CV of IMAC equilibration buffer. The protein was eluted 
with 6 CV of elution buffer II and fractions containing NisPsol were pooled (approx. 
30 mL) and then loaded onto a Sephadex G15 column (XK 50/30, 300 mL bed volume) 
for desalting using a buffer containing 100 mM MES at pH 6.5. Next, glycerol was added 
to a final volume fraction of 10%, the protein amount was adjusted to 20 µg mL−1 and 
the protease was frozen at −80 °C.
If NisP was produced as membrane-bound variant (e.g. for L. lactis as sensor 
strain), plasmid pNG-nisTP-gfp was used. The plasmid is based on pNG-nisTP that 
was modified to carry the gene for tdGFP. The modification was done as described for 
pNZE3-nisA-mcherry using primers pNZE3pNG-NheI-fw and pNZE3pNG-BamHI-rv 
for enzymatic inverse PCR and cloning the gene for tdGFP from plasmid pKQV5-tdgfp 
using primers tdgfp-NdeI-fw and tdgfp-HindIII-BamHI-rv.
Measurement of MICs
For MIC measurements, the HPLC-purified and lyophilized peptides were resuspended 
in 1 mL of an 0.05% aqueous acetic acid solution and analyzed by HPLC as described 
above. The concentration was measured using the area under the curve at 205 nm and 
peptide-specific absorption properties41,42. For MIC assays, the bacteria were grown 
overnight on strain-specific agar plates. The peptides were diluted with 0.05% acetic 







exact amount of peptide in the dilution was again quantified via HPLC. MICs were 
measured as microdilution assay in 96-well flat bottom polypropylene plates (Greiner) 
and performed as described by Wiegand et al.43. The plates were sealed (airtight alu-
minum foil) and incubated for 18 h without shaking at the strain-specific temperature 
before reading the OD600 using an Infinite Pro F200 plate reader (Tecan, Männedorf, 
Switzerland). The MIC value was set as the minimal concentration where no growth 
of the bacterial strain was observed (<5% of the OD600 value of the positive growth 
control in column 11). MIC experiments were performed in triplicate.
Mass-spectrometric characterization of peptides
Each peptide was analyzed twice, first to determine the number of dehydrations and 
second to quantify the sulfhydryl groups. The difference between the two was then used 
to elucidate the number of thioether-rings that must have been formed. Dehydrations 
were characterized by mass shifts of −18 Da, sulfhydryls were measured indirectly by 
derivatization of those groups with 1-cyano-4-dimethylaminopyridinium tetrafluoro-
borate (CDAP) resulting in a mass shift of +25 Da. For analysis, the HPLC-purified 
and lyophilized peptides were resuspended in 0.05% aqueous acetic acid to reach a 
concentration of 1 to 5 mg mL−1. Next, 25 µL of the peptide was mixed with 1 µL of a 
500 mM tris(2-carboxyethyl)phosphine solution (TCEP, in water, freshly prepared) in 
HPLC glass vials (>10-fold molar excess of TCEP) and incubated for 10 min at room 
temperature. For quantification of dehydrations, 24 µL of an 0.05% aqueous acetic acid 
solution was added and the sample was immediately measured. For quantification of 
sulfhydryls, 24 µL of a 178 mM CDAP (in 0.05% aqueous acetic acid, freshly prepared) 
was added (>100-fold molar excess of CDAP) and incubated for 30 min at room tem-
perature prior measurement.
Measurements were performed using an Agilent 1200 series HPLC system cou-
pled to an Ab Sciex 4000 QTRAP triple quadrupole mass spectrometer and using 
electrospray ionization (ESI). The device was calibrated prior measurement using 
the MS Chemical Kit 1, Low-High Conc. PPGs (Ab Sciex, 4406127) according to 
the manufacturer’s recommendation. An aliquot of 2 µL of the sample was injected 
onto an RPC18 column (ReproSil-Pur 120 C18-AQ 3 µm, 150 × 2 mm, 5 × 2 mm 
precolumn, Dr. Maisch) heated to 30 °C. The HPLC parameters were the same as for 
the peptide quantification (see above) but using formic acid instead of TFA. The mass 
spectrometer was operated in Q1 mode. The parameters for the TurboIonSpray probe: 
ion spray voltage (IS): 5,000 V, positive polarity, temperature (TEM): 300 °C, curtain 
gas (CUR): 20 psig, ion source gas 1 (GS1): 70 psig, ion source gas 2 (GS2): 60 psig, 
interface heater (ihe): ON and the settings for the MS: declustering potential (DP): 60 V, 
entrance potential (EP): 10 V, collision cell rod offset (RO2): −60 V, Q3 rod offset (RO3): 








Each sample was analyzed twice, a first explorative scan from 500 to 2,000 m z−1 
at a scan rate of 1,000 Da s−1 was followed by a precise scan covering a window of 
100 m z−1 at a scan rate of 250 Da s−1 for a maximum of three charge states.
The data was processed using a script written in the programming language R 
and employing the MALDIquant package44. The data was deconvoluted, averaged and 
centroided (signal-to-noise threshold: 5%). The results where then compared to the cal-
culated peptide masses41 to determine the number of dehydrations or sulfhydryl groups.
Statistical analysis
For nanoFleming screening, statistical parameters consisted of the absolute number 
of nLRs analyzed, the numbers of nLRs within the low and high green fluorescence 
subpopulations as well as the mean green fluorescence, its standard derivation (SD) 
and coefficient of variation (CV). All parameters were calculated using the Flow Pilot 
software (version 1.3.08, Union Biometrica) directly during screening. For MIC mea-
surements, only those experiments were considered as reproducible where the spread of 
the three MIC values defined as log2(MICmax - MICmin) was ≤2. The statistical evalu-
ation of the MIC values was done with a script written in the programming language R.
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Supplementary Figures and Tables
Supplementary Figure 1. Post-translational modification machinery. Four different enzymes (NisB, NisC, 
NisT, and NisP) were used for post-translational processing and secretion of the combinatorial peptides. 
Furthermore, to direct the non-modified precursor peptide synthesized at the ribosome to the modification 
machinery, the peptides were fused to the leader peptide of nisin. After ribosomal synthesis, the dehydratase 
NisB dehydrates serine and threonine residues to dehydroalanine or dehydrobutyrine, respectively. Next, 
the cyclase NisC catalyzes ring formation via a nucleophilic attack of a cysteine residue to the dehydroam-
ino acids following a Michael addition type reaction mechanism leading to the formation of lanthionine 
(after dehydration of serine) or methyllanthionine (after dehydration of threonine). Next, NisT secretes 
the peptide to the extracellular space. For activation, the leader-specific protease NisP cleaves the leader 
peptide to release the active core peptide. Note that while wild-type NisP is membrane-bound, we used 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 4. Diffusion and crosstalk of nisin among nLRs. (a) Two nLR incubation methods 
were compared. First, the incubation of nLRs was solely done in aqueous phase (CDMS growth medium). 
Peptides secreted by the candidate strain L. lactis NZ9000 [pIL3BTC, pNZE3nisAmcherry] can therefore 
diffuse not only inside the nLR but eventually also leave the nLR which might lead to incomplete inhibition 
of the sensor growth inside the nLR as shown by microscopic analysis (left picture, images are overlays 
of bright-field and epifluorescence images using the GFP and mCherry filter set). Note the gradient of 
the sensor growth in the right nLR. In contrast, if incubation is performed in a hydrophobic phase (right 
picture), growth inhibition of the sensor is complete throughout the nLR. Scale bars: 200 µm. (b) To test 
whether the diffusion of peptides out of the reactors during aqueous incubation can also lead to an inhi-
bition of cells in other nLRs in the same incubation batch we mixed nLRs containing either colonies of 
the candidate strain L. lactis NZ9000 [pIL3BTC, pNZE3-nisA-mcherry] or colonies of the NisP-producing 
sensor strain L. lactis NZ9000 [pNGnisTPtdgfp] (on average 1 colony nLR1, Poisson diluted). The nLRs 
were then mixed in separated batches (2,000 nLR mL-1 each) in fixed ratios with increasing amounts of 
candidate-containing nLRs (0, 100, 250, 500, 1,000 nLR mL-1) and decreasing numbers of sensor-containing 
nLRs (2,000, 1,900, 1,750, 1,500, 1,000 nLR mL-1). After mixing of the nLRs in CDMS, peptide-production 
was induced with 5 ng mL−1 nisin and the nLRs where incubated for 18 h. After incubation, nLRs where 
recovered from the medium and the size of the sensor colonies was measured. We could observe a decreas-
ing colony size of the sensor colonies when increasing amounts of candidate colonies were co-incubated 
with the sensors. This indicates a crosstalk between the nLRs allowing a diffusion of the peptides from 
the ‘candidate’ nLRs to the ‘sensor’ nLRs and thus inhibiting the growth of those cells. Bars represent the 



















Supplementary Figure 5. Characterization of the nanoFleming assay. (a) A mixture of two different L. lactis 
strains was encapsulated. The first strain, L. lactis NZ9000 [pIL3BTC, pNZE3-nisA-mcherry] secretes 
prenisin (left side, ‘+’), and the second strain L. lactis NZ9000 [pIL3BTC, pNZE3-rdm-mcherry] does 
not secrete any antimicrobial peptide (right side, ‘-’). The cells were co-encapsulated with the NisP-pro-
ducing sensor strain L. lactis NZ9000 [pNG-nisTPtdgfp], grown for 18 h in an hydrophobic phase, and 
then analyzed by large-particle flow cytometry, gated on the presence of a colony (as indicated by the red 
fluorescence of the colonies) and plotted for their green fluorescence levels. (b) Mean green fluorescent 
levels of the nLRs indicate a difference of approx. 25-fold between nLRs harboring a prenisin producing 
strain and nLRs that do not. Bars represent the mean of 71 (+) and 984 (-) nLRs (n = 71, n = 984), error 








Supplementary Figure 6. Sensitivity of the nanoFleming assay. Three different nisin hinge region variants, 
NMK (nisin wild-type), GLV (nisin hinge-variant 1) and GGC (nisin hinge-variant 2) were produced 
by strain L. lactis NZ9000 [pIL3BTC, pNZE3-nisA_x-mcherry] (where x stands for the hinge region 
variant) and tested for their inhibition profiles against the NisP producing sensor strain L. lactis NZ9000 
[pNGnisTPtdgfp] with two assay types: a standard inhibition zone assay performed on a petri dish and 
the nanoFleming assay. In the petri dish assay, the nisin wild-type resulted in the formation of a large 
halo whereas the two variants with modulated hinge regions showed a reduction in halo size. In fact, 
the hinge-variant 2 resulted in a halo just above the detection limit of the assay (orange arrows). When 
embedded in nLRs, results followed the same trend. The wild-type hinge region led to the strongest re-
duction in sensor growth (as measured by large-particle flow cytometry analyzing the green fluorescence 
of the sensor strain) here the mean green fluorescence intensity of the peak containing the nLRs with low 
sensor content (left fringe of the histogram) was the lowest for the wild-type hinge region (20 AU), while 
growth-reduction obtained from the hinge-variant 2 was considerably weaker (33 AU). However, the 
population not secreting a peptide (strain L. lactis NZ9000 [pIL3BTC, pNZE3-rdm-mcherry]) was well 
separated from the peptide secreting population in each of the three cases (>3 σ from the mean of the 































































































































































































































































































































































































































































































































































































Supplementary Figure 9. MIC distribution of purified peptides against M. flavus. Distribution of minimal 
inhibitory concentrations of 31 purified peptides against M. flavus. Values in the histogram are means of 





















































































































































































































































































































































































































































































































































Supplementary Figure 11. Mass spectrometric characterization of selected peptides. Masses and PTMs of 
12 peptides I: Amino acid sequence of the peptide; serines and threonines (in orange) can be dehydrated 
by NisB resulting in a mass shift of −18 Da (✸) whereas cysteine residues (in blue) that are not involved in 
thioether ring formation catalyzed by NisC and thus carry sulfhydryl groups can be derivatized by CDAP 
resulting in a mass shift of +25 Da (♦). Cysteines that do not undergo derivatization by CDAP are used 
to calculate the number of thioether rings that must have been formed. II: Chromatogram at 205 nm of 
the HPLC purified peptide. Purity at 205 nm for the main peptide peak. III: Calculated peptide masses 
compared to the values observed by mass spectrometry. Matches of calculated vs. observed masses (dif-
ference ≤0.5 Da) are indicated in green IV: Mass spectrum of the peptide, peaks matching the calculated 
peptide mass are highlighted in green. V: Mass spectrum after treatment with CDAP, peaks matching the 
calculated peptide mass are highlighted in green. (a) Characterization of nisin. To prove derivatization of 
the sulfhydryl groups by CDAP, a nisin peptide produced by a strain lacking the NisC enzyme (L. lactis 



















Supplementary Table 1. Wild-type peptide sequences used in this study.
Peptide Sequence
Nisin I T S I S L C T P G C K T G A L M G C N M K T A T C H C S I H V S K
Subtilin W K S E S L C T P GC V T G A L Q T C F L Q T L T C N C K I S K
Gallidermin I A S K F LC T P G C A K T G S F N S Y C C
Mutacin B-Ny266 F K S W S F C T P G CA K T G S F N S Y C C
Pep5 T A G P A I R A S V K Q C Q K T L K A T R L F T V S C K G K N G C K
Epicidin 280 S L G P A I K A T R Q V C P K A T R F V T VS C K K S D C Q
Epilancin K7 S A S V L K T S I KV S K K Y C K G V T L T C G C N I T G G K
Paenibacillin A S I I K T T I K V S K A V C K T L T C I C T G S C S N C K
Lacticin 481 K G G S G V I H T I S H E C N M N S W Q F V F T C C S
Actagardine S S G W V C T L T I E C G T V I C A C
Lactocin S S T P V L A S V A V S M E L L P T A S V L Y S D V A G C F K Y S A K H H C
Haloduracin α C A W Y N I S C R L G N K G A Y C T L T V E C M P S C N























B1 B2 P1 P2 P3
SC5.0069 Nisin Nisin Nisin Epilancin K7 Nisin 0.27
SC5.0086 Gallidermin Gallidermin Nisin Synthetic 3 Nisin 0.59
SC5.0189 Nisin Nisin Nisin Synthetic 3 Epilancin K7 3.37
SC5.0333 Nisin Nisin Nisin Pep 5 Other 0.49
9 SC5.0364 Nisin Nisin Nisin Synthetic 3 Pep 5 0.44
11 SC5.0479 Nisin Nisin Nisin Synthetic 2 Epilancin K7 1.03
SC5.0487 Nisin Gallidermin Actagardine Epilancin K7 Pep 5 3.82
SC5.0515 Nisin Gallidermin Nisin Gallidermin Lactocin S 3.03
SC5.0531 Gallidermin Gallidermin Mutacin B-Ny266 Synthetic 4 Epilancin K7 0.55
7 SC5.0718 Nisin Nisin Nisin Pep 5 Lactocin S 0.45
6 SC5.0925 Nisin Gallidermin Nisin Synthetic 3 Nisin 0.87
SC5.0953 Gallidermin Nisin Nisin Synthetic 2 Nisin 0.08
SC5.1048 Gallidermin Nisin Actagardine Synthetic 3 Epilancin K7 14.1
SC5.1237 Nisin Nisin Actagardine Synthetic 3 Nisin 2.08
2 SC5.1421 Gallidermin Gallidermin Nisin Synthetic 1 Nisin 0.21
SC5.1491 Nisin Gallidermin Nisin Epilancin K7 Nisin 5.11
SC5.1516 Nisin Gallidermin Actagardine EpilancinK7 Lactocin S 2.90
5 SC5.1536 Nisin Nisin Nisin Synthetic 4 Nisin 0.59
SC5.1620 Nisin Gallidermin Nisin Synthetic 1 Nisin 0.33
4 SC5.1659 Nisin Nisin Nisin Synthetic 2 Nisin 0.14
SC5.1743 Nisin Nisin Nisin Synthetic 3 Nisin 0.14
SC5.1922 Gallidermin Gallidermin Actagardine Synthetic 3 Epilancin K7 33.8
8 SC5.2096 Nisin Nisin Nisin Nisin Pep 5 0.18
10 SC5.2354 Nisin Nisin Nisin Synthetic 4 Paenibacillin 2.95
SC5.2630 Nisin Nisin Nisin Synthetic 4 Epilancin K7 2.29
SC5.2701 Nisin Nisin Paenibacillin Synthetic 1 Lactocin S 1.49
1 SC5.2712 Gallidermin Gallidermin Nisin Nisin Nisin 0.13
SC5.2829 Nisin Gallidermin Nisin Nisin Nisin 0.15
3 SC5.2930 Gallidermin Nisin Nisin Synthetic 3 Nisin 0.04
SC5.9487 Gallidermin Epicidin 280 Paenibacillin Pep 5 Nisin 1.14




















Supplementary Table 3. DNA oligonucleotides used in this study.






























Underlined bases indicate restriction sites (see oligonucleotide name for enzyme).








Supplementary Table 4. Bacterial strains used in this study.
ID Name Genotype Reference
1 M. flavus NIZO B423 NIZO food research
2 L. lactis NZ9000 MG1655 pepN::nisRnisK 1
3 L. lactis NZ9800 NZ9700 ∆nisA 2
4 L. lactis NZ9803 NZ9800 ∆nisP ∆nisA This work
5 S. aureus ATCC 29213 methicillin sensitive (MSSA) 3
6 S. aureus ATCC 33591 methicillin resistant (MRSA) 3,4
7 S. aureus CAL methicillin resistant (MRSA) The University  Medical 
Center Groningen, 
The Netherlands
8 S. aureus MW2 methicillin resistant (MRSA) The University  Medical 
Center Groningen, 
The Netherlands
9 E. faecalis ATCC 29212 vancomycin sensitive (VSE) 3
10 E. faecalis ATCC 51575 gentamicin, streptomycin, and vancomy-
cin resistant (VRE) 
3,5
11 E. faecalis LMG 16216 vancomycin resistant (VRE) Laboratory of Microbiology, 
Gent, Belgium
12 E. faecium LMG 16003 avoparcin and vancomycin resistant 
(VRE)





14 S. pneumoniae D39 serotype 2 6
15 S. pneumoniae TIGR4 serotype 4 7
16 B. cereus ATCC 14579 8
17 E. coli DH5α F– Φ80 lacZ∆M15 ∆(lacZYA-argF)U169 
recA1 endA1 hsdR17(rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1
9
18 E. coli DB3.1 F– gyrA462 endA1 glnV44 ∆(sr1-recA) 
mcrB mrr hsdS20(rB–, mB–) ara14 galK2 




















Supplementary Table 5. Plasmids used in this study.
ID Name Features Reference
1 pIL3BTC pAMβ1 origin of replication, chloramphenicol resis-
tance, expression of nisBTC under control of the Pnis 
promoter
12
2 pNSR pNZ-SV-SaNSR, pSH71 origin of replication, chloram-
phenicol resistance, L. lactis – E. coli shuttle, expression 
of nsr under control of the Pnis promoter
13,14
3 pEmpty pNZ8048, pSH71 origin of replication, chloramphen-
icol resistance, L. lactis – E. coli shuttle, Pnis promoter 
and empty multiple cloning site
1
4 pQL11 pUC origin of replication, ampicillin resistance, carries 
the ccdB expression cassette
15
5 pSEVA241 ColE1 origin of replication, kanamycin resistance 16
6 pSEVA241-silent as pSEVA241, carries cassette for ccdB expression This work
7 pSEVA241-library as pSEVA241, carries the leader-less library This work
8 pNZE3-nisA pSH71 origin of replication, erythromycin resistance, 
L. lactis – E. coli shuttle, expression of nisA under 
control of the Pnis promoter
17
9 pSB1C3-BBa_J06504 pMB1 origin of replication, chloramphenicol resis-
tance, carries the gene for mCherry (BioBrick part 
BBa_J06504)
18,19
10 pNZE3-nisA-mcherry as pNZE3-nisA, expression of mcherry under control of 
the P23 promoter
This work
11 pMA-T-nisAopt pRO1600/ColE1 origin of replication, ampicillin 





as pNZE3-nisA-mcherry, carries a codon-optimized 
nisin leader and nisA gene separated by a NheI site for 
cloning and fused to the Pnis promoter
This work
13 pNZE3-rdm-mcherry as pNZE3-nisAopt-mcherry, carries a random sequence 
instead of the nisA structural gene
This work
14 pNZE3-library-mcherry as pNZE3-nisAopt-mcherry, carries the library instead 
of the nisA structural gene
This work
15 pIL3BT pIL3BTC derived, lacking the gene for NisC 20
16 pNZ-nisPsol-8H pSH71 origin of replication, chloramphenicol resis-
tance, L. lactis – E. coli shuttle, expression of nisP with 
His8-tag under control of the Pnis promoter
21
17 pNG-nisTP pSH71 origin of replication, chloramphenicol resis-
tance, L. lactis – E. coli shuttle, expression of nisP under 
control of the Pnis promoter
17
18 pKQV5-tdgfp pBR322 origin of replication, ampicillin resistance, 
expression of tdgfp under control of the Ptac promoter
22
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